

IN THE CLAIMS:

Please amend the claims by canceling claims 23-28 and adding new claims 29-50 according to the following, current listing of claims with markings to show changes made.

Current Listing of Claims:

Claims 1-22 (Previously Cancelled)

Claims 23-28 (Cancelled)

29. (New) An intranasal formulation effective for preventing and/or treating nausea and/or vomiting in a mammalian subject comprising scopolamine and polyvinyl alcohol (PVA), said formulation having a pH below about pH 4.0.

30. (New) An intranasal formulation according to claim 29, wherein said scopolamine is scopolamine hydrobromide.

31. (New) An intranasal formulation according to claim 29, wherein said pH of the formulation is about 3.5.

32. (New) An intranasal formulation according to claim 29, wherein said PVA is present in a concentration of about 10%.

33. (New) An intranasal formulation according to claim 29, wherein said formulation further comprises a buffer salt selected from citric acid and sodium citrate.

34. (New) An intranasal formulation according to claim 29, wherein said formulation further comprises a buffer salt in a concentration less than or equal to 100 mM.

35. (New) An intranasal formulation according to claim 34, wherein said buffer salt concentration is less than or equal to 50 mM.

36. (New) An intranasal formulation according to claim 34, wherein said buffer salt concentration is about 20 mM.

37. (New) An intranasal formulation according to claim 29, wherein said PVA is combined with one or more additional gelling agents or bio-adhesives selected from alginates, gums, starches, polyacrylates, dextrans, chitosans and mixtures thereof.

38. (New) An intranasal formulation according to claim 29, further comprising one or more additional ingredient(s) selected from buffering agents, thickening agents, tolerance enhancers, surfactants, excipients, preservatives and combinations thereof.

39. (New) An intranasal formulation according to claim 38, wherein the preservative is benzalkonium chloride.

40. (New) A method for preventing and/or treating nausea and/or vomiting in a mammalian subject comprising administering intranasally to said subject a nasal delivery formulation of scopolamine and polyvinyl alcohol (PVA), wherein said formulation has a pH below about pH 4.0.

41. (New) The method of claim 40, wherein said scopolamine is scopolamine hydrobromide.

42. (New) The method of claim 40, wherein said pH of the formulation is about 3.5.

43. (New) The method of claim 40, wherein said PVA is present in a concentration of about 10%.

44. (New) The method of claim 40, wherein said formulation further comprises a buffer salt selected from citric acid and sodium citrate.

45. (New) The method of claim 40, wherein said formulation further comprises a buffer salt in a concentration less than or equal to 100 mM.

46. (New) The method of claim 45, wherein said buffer salt concentration is less than or equal to 50 mM.

47. (New) The method of claim 45, wherein said buffer salt concentration is about 20 mM.

48. (New) The method of claim 40, wherein said polyvinyl alcohol is combined with one or more additional gelling agents or bio-adhesives selected from alginates, gums, starches, polyacrylates, dextrans, chitosans and mixtures thereof.

49. (New) The method of claim 40, further comprising one or more additional ingredient(s) selected from buffering agents, thickening agents, tolerance enhancers, surfactants, excipients, preservatives and combinations thereof.

50. (New) The method of claim 40, wherein the preservative is benzalkonium chloride.